BNP Paribas Arbitrage SA raised its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 203.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 135,497 shares of the biopharmaceutical company’s stock after acquiring an additional 90,799 shares during the quarter. BNP Paribas Arbitrage SA owned approximately 0.06% of Alexion Pharmaceuticals worth $19,009,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Commerzbank Aktiengesellschaft FI boosted its stake in shares of Alexion Pharmaceuticals by 151.5% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 132,698 shares of the biopharmaceutical company’s stock valued at $16,145,000 after buying an additional 79,943 shares during the period. HPM Partners LLC boosted its stake in shares of Alexion Pharmaceuticals by 267.2% in the 2nd quarter. HPM Partners LLC now owns 6,680 shares of the biopharmaceutical company’s stock valued at $656,000 after buying an additional 4,861 shares during the period. Principal Financial Group Inc. boosted its stake in shares of Alexion Pharmaceuticals by 1.2% in the 2nd quarter. Principal Financial Group Inc. now owns 335,525 shares of the biopharmaceutical company’s stock valued at $40,823,000 after buying an additional 4,115 shares during the period. Assenagon Asset Management S.A. boosted its stake in shares of Alexion Pharmaceuticals by 4,509.0% in the 3rd quarter. Assenagon Asset Management S.A. now owns 884,150 shares of the biopharmaceutical company’s stock valued at $124,037,000 after buying an additional 864,967 shares during the period. Finally, IFC Holdings Incorporated FL purchased a new position in shares of Alexion Pharmaceuticals in the 3rd quarter valued at about $861,000. 94.60% of the stock is owned by institutional investors.

Alexion Pharmaceuticals, Inc. (ALXN) traded down $1.20 during trading hours on Friday, hitting $115.17. The stock had a trading volume of 1,521,700 shares, compared to its average volume of 2,487,436. The firm has a market capitalization of $25,730.13, a price-to-earnings ratio of 23.55, a P/E/G ratio of 1.26 and a beta of 1.22. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.51 and a current ratio of 2.96. Alexion Pharmaceuticals, Inc. has a 1-year low of $96.18 and a 1-year high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.32 by $0.12. The business had revenue of $859.00 million for the quarter, compared to analyst estimates of $864.34 million. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 earnings per share. analysts expect that Alexion Pharmaceuticals, Inc. will post 4.81 earnings per share for the current fiscal year.

Several equities analysts have recently issued reports on ALXN shares. Royal Bank Of Canada lifted their price objective on Alexion Pharmaceuticals to $166.00 in a research note on Tuesday, October 24th. SunTrust Banks, Inc. reiterated a “buy” rating and issued a $180.00 price objective (up previously from $170.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. BidaskClub cut Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 14th. Deutsche Bank AG reiterated a “buy” rating and issued a $158.00 price objective (up previously from $153.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. Finally, Leerink Swann reiterated a “buy” rating and issued a $182.00 price objective on shares of Alexion Pharmaceuticals in a research note on Monday, September 25th. Six investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $154.01.

WARNING: “BNP Paribas Arbitrage SA Grows Holdings in Alexion Pharmaceuticals, Inc. (ALXN)” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.thecerbatgem.com/2017/11/12/bnp-paribas-arbitrage-sa-grows-holdings-in-alexion-pharmaceuticals-inc-alxn.html.

In other news, Director Ann M. Veneman sold 835 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total value of $121,751.35. Following the transaction, the director now owns 5,480 shares of the company’s stock, valued at $799,038.80. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Julie O’neill sold 4,375 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $145.44, for a total value of $636,300.00. Following the completion of the transaction, the executive vice president now directly owns 26,092 shares in the company, valued at approximately $3,794,820.48. The disclosure for this sale can be found here. In the last three months, insiders sold 16,490 shares of company stock worth $2,337,251. Corporate insiders own 4.35% of the company’s stock.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.